Vera Therapeutics (VERA) Earnings Call Presentation

Efficacy Results - Atacicept demonstrated long-term stabilization of eGFR (estimated glomerular filtration rate) in IgAN patients over 96 weeks[31] - Atacicept treatment resulted in a sustained 66% reduction in Gd-IgA1 levels[20] - There was a notable 52% reduction in proteinuria (UPCR) with atacicept treatment over the 96-week study period[20] - Atacicept led to a 75% resolution of hematuria in treated participants[20] - The annualized eGFR slope with atacicept was -0.6 mL/min/1.73 m2 per year, comparable to the general population without kidney disease[20] Safety Profile - Atacicept was generally well-tolerated over 96 weeks, with an adverse event profile consistent with the initial 36-week randomized period[27] - During the double-blind phase, 73% of participants in the atacicept group experienced treatment-emergent adverse events (TEAEs)[27] - In the open-label extension (OLE) phase, 77% of participants experienced TEAEs[27] - Serious TEAEs were reported in 2% of participants during the double-blind phase and 11% during the OLE phase[27] - Discontinuation due to TEAEs occurred in 1% of participants during the double-blind phase and 2% during the OLE phase[27]